theMednetRegister

Thoracic Malignancies

Genitourinary Cancers   

Questions discussed in this category

What are your top takeaways from ESMO 2023?
10 Answers available
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
For instance, do you factor availability of RNAseq, inclusion of normal blood controls, and QNS rates into your decision?
1 Answer available
What are best practices for oncologists during the national platinum shortage?
Please specify how your institution is allocating resources now or will be soon.
13 Answers available
When do you refer patients for germline testing when somatic tumor testing is negative for actionable mutations?
How reliable is somatic testing to detect an underlying germline predisposition?
2 Answers available
Do you stop PPI when starting patients on immunotherapy?
1 Answer available
How do you typically prescribe dose to a PTV for standard IMRT plans?
3 Answers available
Would you offer systemic therapy after rendered NED from SRS to isolated CNS metastases in a patient with prior curative intent treatment of lung adenocarcinoma and clear cell RCC?
0 Answers available
What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?
1 Answer available
Do you recommend routine dental evaluation for all patients before starting bisphosponates in patients with bone metastases?
1 Answer available
How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?
Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?
1 Answer available
Do you check baseline or surveillance audiometry (if not overtly symptomatic) to screen for hearing loss in all patients getting cisplatin?
3 Answers available
Should special precautions be taken when treating oligometastatic disease in the sacrum or pelvis with SBRT in a patient with a long life expectancy?
For example in a patient with a good performance status and a biologically favorable cancer (ER+ breast cancer, EGFR+ NSCLC, or prostate cancer), are ...
1 Answer available
Is it safe to deliver SBRT to progressive lung metastases to patients with metastatic RCC receiving concurrent pazopanib?
2 Answers available


Papers discussed in this category

Semin Radiat Oncol, 2004-01-01
Errors and margins in radiotherapy.
Practical radiation oncology, 2017
State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions.
The Lancet. Oncology, 2016-12
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Lancet, 2019 Apr 11
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
JAMA Netw Open, 2020 Feb 05
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Ann Pharmacother, 2021 Jul 20
Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Ann Transl Med,
The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Can Fam Physician,
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
Journal of the National Cancer Institute, 2016-06
An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.
Pediatrics, 2014 Feb 02
Chemotherapy drug shortages in pediatric oncology: a consensus statement.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
The Journal of urology, 2018-12
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
N. Engl. J. Med.,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Lancet Oncol., 2014 Feb 18
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Br J Cancer, 2014 Apr 15
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Cancer, 2011-06-15
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Eur J Cancer, 2017 Nov 28
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
N. Engl. J. Med., 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Lancet Oncol, 2021 Jan 18
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
J Clin Oncol, 2021 Apr 19
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
J Clin Oncol, 2003 Jul 01
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
JAMA network open, 2023 Nov 01
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
The New England journal of medicine, 2023 Jun 04
Overall Survival with Osimertinib in Resected -Mutated NSCLC.
Nature medicine, 2023 Sep 14
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
The New England journal of medicine, 2023 Oct 20
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 05
The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
Lancet (London, England), 2009-10-24
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
N Engl J Med, 2022 Apr 11
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
The New England journal of medicine, 2023 Jun 03
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2023 Oct 21
Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions.
JTO clinical and research reports, 2023 Aug 16
Real-World Response and Outcomes in Patients With NSCLC With Exon 20 Insertion Mutations.
The New England journal of medicine, 2023 Oct 23
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
N Engl J Med, 2021 Jun 23
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Future oncology (London, England), 2021 Jun 08
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
Cancer cell, 2021 Jun 17
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
The New England journal of medicine, 2023 Oct 22
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
The New England journal of medicine, 2023 Oct 21
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 11
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Related Topics in Thoracic Malignancies

Copyright © 2025 theMednet
All Rights Reserved.